Better Mental Health
for More People

Scroll-Down-white

We are at a crisis point
in mental health provision.

Mental health and addiction (including alcohol), is the 5th leading cause of illness globally, affecting 20% of the world’s population.

Unlike other medical disciplines, psychiatry focuses on maintenance rather than cure, and symptom suppression rather than addressing the root causes of these illnesses.

The exception is Psychedelics and Psychedelic-Assisted Psychotherapy which have the potential to radically change mental health services and deliver significantly better patient outcomes.

About Awakn

Asset-44

Awakn Life Sciences is a biotechnology company with clinical operations researching, developing, and delivering psychedelic new chemical entity drugs and therapies to treat Addiction.

We are integrating psychedelic medicine into mainstream healthcare to enable better mental health for more people through Research, Digital, Clinics, and Ecosystems.

We have a dual strategic focus, to develop and commercialise proprietary psychedelic new chemical entity drugs and therapies to treat Addiction and to treat Addiction and other mental health conditions in a chain of medical psychedelic clinics across the UK and EU.

Our goals are to be the leader in biotech research of psychedelic new chemical entity drugs and therapies to treat Addiction, build, own, and operate the UK and EU’s leading chain of medical psychedelic clinics, and scale our reach through our Partnerships Ecosystem.

Why Awakn


Clear IP development pathway

• New chemical entity drugs
• Clinical trials
• Advanced predictive analytics


Multiple revenue streams:

• Clinic revenue starting in 2021.
• Partnership Ecosystem revenue starting in 2022.
• Research revenue in 2026+.


First mover advantage in UK and EU:

400m people and CAD$25trn GDP.


Global research leaders in the field of psychedelic treatments for Addiction:

Dr. Ben Sessa led the world’s only MDMA-Assisted Psychotherapy  and AUD study (BIMA) and Prof. Celia Morgan led the world’s only Ketamine-Assisted Psychotherapy AUD study (KARE).

➄ 
The leading scientific and medical team in the industry:

Prof. David Nutt, Dr. Ben Sessa, Prof. Celia Morgan,, Dr. Michael Mithoefer, Ann Mithoefer, and Prof. Matt Johnson.


Strategic partnerships with two leading UK universities

for exclusive access to data and findings from recent clinics trials.

Divisions

Our business consists of three related and complementary divisions: Research, Digital, Clinics, and Ecosystems.

Awakn Research

Asset-44-1

Our team has led the research that has defined the psychedelic medicine industry, including: the Bristol Imperial MDMA for Alcoholism (BIMA) study and the Ketamine for Reduction of Alcoholic Relapse (KARE).

We have a portfolio of drug development and clinical trials planned and initiated focused on treating addiction.

004
awakn_digital

Awakn Digital

Asset-44-1

Predictive Analytics to improve the efficiency of Psychedelic-Assisted Psychotherapy.


Awakn Clinics

Asset-44

We provide hope for those whom the status quo is not working by combining the proven therapeutic potential of ketamine with psychotherapy to treat Addiction, Anxiety, Depression, and PTSD.

• Bristol Q1 2021
• London 1 & Manchester 2021
• London 2, Birmingham, Dublin (Ireland) 2022
• Continental Europe 2023+

awakn-1
009

Awakn Partnerships Ecosystems

Asset-44-1-2

Scale our reach beyond our core territories through licencing to enable addiction treatment practitioners deliver the Awakn methodology:

Protocols & Therapy

• Training
• Clinic Design Best Practice 
• Data, Analytics, Insights


Corporate Board

georgescorsis

George Scorsis

CHAIR

anthonytennison

Anthony Tennyson

CHIEF EXECUTIVE OFFICER

bensessa

Dr. Ben Sessa

CHIEF MEDICAL OFFICER

david_page

Steve Page

INDEPENDENT NON-EXECUTIVE DIRECTOR

john_papastergiou-1

Prof. John Papastergiou

INDEPENDENT NON-EXECUTIVE DIRECTOR

Leadership Team

anthonytennison

Anthony Tennyson

CHIEF EXECUTIVE OFFICER

jonathanheld

Jonathan Held

CHIEF FINANCIAL OFFICER

jamescollins-1

James Collins

CHIEF OPERATING OFFICER

bensessa

Dr. Ben Sessa

CHIEF MEDICAL OFFICER

lauriehigbed

Dr. Laurie Higbed

LEAD PSYCHOLOGIST

celiamorgan

Prof. Celia Morgan

HEAD OF KETAMINE-ASSISTED 
PSYCHOTHERAPY FOR ALCOHOL 
USE DISORDER PRACTICE

davidnutt-1

Prof. David Nutt

HEAD OF RESEARCH

shaunmcnutty

Dr. Shaun McNulty

CHIEF SCIENCE OFFICER

Scientific Advisory Board

Our pioneering team is made up of some of the leading clinical researchers, scientific minds and clinical experts in the global industry

davidnutt-1

Prof. David Nutt

CHAIR

bensessa

Dr. Ben Sessa

CHIEF MEDICAL OFFICER

celiamorgan

Prof. Celia Morgan

HEAD OF KETAMINE-ASSISTED 
PSYCHOTHERAPY FOR ALCOHOL 
USE DISORDER PRACTICE

annmithoefer

Ann Mithoefer, BSN

ADVISOR

michael-mithoefer

Dr. Michael Mithoefer

ADVISOR

matthewjohnson

Prof. Matthew W.  Johnson

ADVISOR

Latest News

Video Resources

alcohol_study

Dr. Ben Sessa live on Euronews

nutt

Prof. David Nutt: TEDx

Ben

Dr. Ben Sessa: TEDx

oo5

Revealing the Mind: The Promise of Psychedelics

Contact

Awakn_logo_descriptor-02-1

MAIN OFFICE
Suite 200, 366 Bay St,
Toronto, Ontario, M5H 4B2, Canada


UK OFFICE
1 Regent Street,
Bristol, BS8 4HW, United Kingdom

For all enquiries, complete the form and we’ll be in touch.

© 2021 Awakn Life Sciences Inc      |      Privacy Policy      |      Appropriate Use Policy